CN113412124A - Baff-r双特异性t细胞衔接子抗体 - Google Patents

Baff-r双特异性t细胞衔接子抗体 Download PDF

Info

Publication number
CN113412124A
CN113412124A CN201980089634.XA CN201980089634A CN113412124A CN 113412124 A CN113412124 A CN 113412124A CN 201980089634 A CN201980089634 A CN 201980089634A CN 113412124 A CN113412124 A CN 113412124A
Authority
CN
China
Prior art keywords
seq
chain variable
variable domain
recombinant protein
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980089634.XA
Other languages
English (en)
Chinese (zh)
Inventor
H·秦
L·W·郭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Priority to CN202511607565.0A priority Critical patent/CN121405815A/zh
Publication of CN113412124A publication Critical patent/CN113412124A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980089634.XA 2018-12-19 2019-12-19 Baff-r双特异性t细胞衔接子抗体 Pending CN113412124A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511607565.0A CN121405815A (zh) 2018-12-19 2019-12-19 Baff-r双特异性t细胞衔接子抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782317P 2018-12-19 2018-12-19
US62/782,317 2018-12-19
PCT/US2019/067563 WO2020132291A1 (en) 2018-12-19 2019-12-19 Baff-r bispecific t-cell engager antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511607565.0A Division CN121405815A (zh) 2018-12-19 2019-12-19 Baff-r双特异性t细胞衔接子抗体

Publications (1)

Publication Number Publication Date
CN113412124A true CN113412124A (zh) 2021-09-17

Family

ID=71098268

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980089634.XA Pending CN113412124A (zh) 2018-12-19 2019-12-19 Baff-r双特异性t细胞衔接子抗体
CN202511607565.0A Pending CN121405815A (zh) 2018-12-19 2019-12-19 Baff-r双特异性t细胞衔接子抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511607565.0A Pending CN121405815A (zh) 2018-12-19 2019-12-19 Baff-r双特异性t细胞衔接子抗体

Country Status (8)

Country Link
US (2) US20200199232A1 (cg-RX-API-DMAC7.html)
EP (1) EP3897720A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022515152A (cg-RX-API-DMAC7.html)
KR (1) KR20210104816A (cg-RX-API-DMAC7.html)
CN (2) CN113412124A (cg-RX-API-DMAC7.html)
AU (1) AU2019404282A1 (cg-RX-API-DMAC7.html)
CA (1) CA3123599A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020132291A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN116997573A (zh) * 2020-10-15 2023-11-03 佳努克斯治疗公司 靶向psma和cd3的抗体及其用途
US20240034807A1 (en) * 2021-02-16 2024-02-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to mesothelin polypeptides
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
JP2025523874A (ja) * 2022-07-19 2025-07-25 ノバルティス アーゲー Baff又はbaff受容体阻害抗体でのaihaの治療
CN121464157A (zh) * 2023-02-28 2026-02-03 梅约医学教育与研究基金会 结合至b细胞活化因子受体多肽的分子
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242077A1 (en) * 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
CN104780940A (zh) * 2012-11-06 2015-07-15 拜耳制药股份公司 用于双特异性t细胞衔接体(bites)的制剂
WO2016016415A1 (en) * 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
US20170218077A1 (en) * 2016-02-03 2017-08-03 Amgen Research (Munich) Gmbh Bcma and cd3 bispecific t cell engaging antibody constructs
WO2017214170A2 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r antibodies and uses thereof
WO2017214167A1 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
US20180057593A1 (en) * 2015-05-01 2018-03-01 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
US20180117152A1 (en) * 2015-06-16 2018-05-03 Genentech, Inc. Anti-cd3 antibodies and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4733635B2 (ja) * 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
TWI811023B (zh) * 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
KR20210129125A (ko) * 2019-02-20 2021-10-27 시티 오브 호프 Baff-r/cd19 표적화된 키메라 항원 수용체-변형된 t 세포 및 그의 용도

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104780940A (zh) * 2012-11-06 2015-07-15 拜耳制药股份公司 用于双特异性t细胞衔接体(bites)的制剂
US20140242077A1 (en) * 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2016016415A1 (en) * 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
US20180057593A1 (en) * 2015-05-01 2018-03-01 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
US20180117152A1 (en) * 2015-06-16 2018-05-03 Genentech, Inc. Anti-cd3 antibodies and methods of use
US20170218077A1 (en) * 2016-02-03 2017-08-03 Amgen Research (Munich) Gmbh Bcma and cd3 bispecific t cell engaging antibody constructs
WO2017214170A2 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r antibodies and uses thereof
WO2017214167A1 (en) * 2016-06-06 2017-12-14 City Of Hope Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRIEDERIKE BRAIG ET AL.: "Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking", 《BLOOD》, vol. 129, no. 1, pages 100, XP086676899, DOI: 10.1182/blood-2016-05-718395 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用

Also Published As

Publication number Publication date
US20200199232A1 (en) 2020-06-25
JP2025032075A (ja) 2025-03-11
CN121405815A (zh) 2026-01-27
KR20210104816A (ko) 2021-08-25
AU2019404282A1 (en) 2021-07-01
JP2022515152A (ja) 2022-02-17
US20220056132A1 (en) 2022-02-24
EP3897720A1 (en) 2021-10-27
EP3897720A4 (en) 2022-12-07
CA3123599A1 (en) 2020-06-25
WO2020132291A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
JP7391510B2 (ja) ヒト化抗cd73抗体
JP7143452B2 (ja) CD47とSIRPaの相互作用を遮断できる抗体及びその応用
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
JP7275446B2 (ja) Baff-r抗体及びその使用
CN121405815A (zh) Baff-r双特异性t细胞衔接子抗体
JP7070932B2 (ja) Baff-r標的化キメラ抗原受容体修飾t細胞及びその使用
CN116077647B (zh) 喹啉衍生物与抗体的药物组合
US20200392239A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
BR112020016944A2 (pt) Domínios variáveis de anticorpo que alvejam cd33 e uso dos mesmos
JP2022514693A (ja) Muc18に特異的な抗体
KR20230010221A (ko) 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도
CN113474362A (zh) 对cd44特异性的抗体
WO2021115303A1 (zh) 一种抗Claudin18.2单克隆抗体、其制备方法及用途
JP2022514786A (ja) Muc18に特異的な抗体
TW201916890A (zh) 抗pd-1抗體和抗lag-3抗體聯合在製備治療腫瘤的藥物中的用途
JP2008519028A (ja) B細胞悪性腫瘍の治療
KR20240072932A (ko) B7-h3에 특이적으로 결합하는 항체
TW202019962A (zh) 標靶CD38及TGF-β的組合療法
WO2024255467A1 (en) Anti-ccr8 antibody and anti-ccr8/ctla4 bispecific antibody
CN106963950B (zh) 用于治疗肿瘤的联合用药物
HK40098230A (en) Antibodies against cd112r and uses thereof
HK40060753A (en) Antibodies specific to muc18
HK1240845A1 (en) Combination medicine for tumor treatment
HK1240845A (en) Combination medicine for tumor treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination